Pfizer Corporation

Amgen Fremont Inc.

Other

Abgenix, Inc.

Eileen Elliott Mueller

Jose Corvalan

C Geoffrey Davis

Douglas Charles Hanson

Steven Christopher Gilman

Mark Joseph Neveu

Jeffrey Herbert Hanke

Todd A Blumenkopf

Eric Jan Roskamp

Jose Ramon Corvalan

In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucleotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.

Human monoclonal antibodies to CTLA-4

Methods of treating cancer with human monoclonal antibodies to CTLA-4

In accordance with the present invention, there are provided fully human monoclonal antibodies against human cytotoxic T-lymphocyte antigen 4 (CTLA-4). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly contiguous heavy and light chain sequences spanning the complementarity determining regions (CDRs), specifically from within FR1 and/or CDR1 through CDR3 and/or within FR4, are provided. Further provided are antibodies having similar binding properties and antibodies (or other antagonists) having similar functionality as antibodies disclosed herein.

Nucleic acids encoding human monoclonal antibodies to CTLA-4

Methods and host cells for producing human monoclonal antibodies to CTLA-4

Methods for expressing and recovering human monoclonal antibodies to CTLA-4

2,4-diaminopyrimidine compounds useful as immunosuppressants

Growing community of inventors

Old Lyme, CT, United States of America

Eileen Elliott Mueller